Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| CORMEDIX | 10 | 10 | -34,80 % | ||
| ALUMIS | 8 | 2 | +11,35 % | ||
| AURA BIOSCIENCES | 7 | - | -0,29 % | ||
| AXSOME THERAPEUTICS | 6 | 1 | -5,06 % | ||
| ILLUMINA | 6 | - | +0,38 % | ||
| NEUROGENE | 5 | 1 | +0,80 % | ||
| CRISPR THERAPEUTICS | 4 | 1 | -2,54 % | ||
| LARIMAR THERAPEUTICS | 3 | 4 | +0,92 % | ||
| KALVISTA PHARMACEUTICALS | 3 | 1 | -3,54 % | ||
| ARTIVA BIOTHERAPEUTICS | 3 | - | -3,94 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18:15 | Geron (NASDAQ:GERN) Trading Down 3% - Time to Sell? | 1 | MarketBeat | ||
| 18:15 | Amicus Therapeutics (NASDAQ:FOLD) Stock Price Down 2.5% - Should You Sell? | 1 | MarketBeat | ||
| 18:15 | IBD 50's Axsome Therapeutics Dives On Mixed ADHD Results. Why Analysts Aren't Worried. | 1 | Investor's Business Daily | ||
| 18:12 | Tevogen Bio Inc: Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan | 1 | GlobeNewswire (USA) | ||
| 18:10 | Will Alkermes' Proprietary Drugs Aid Growth Amid Stiff Competition? | 1 | Zacks | ||
| 17:54 | Here's How Much $100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today | 1 | Benzinga.com | ||
| 17:10 | Axsome touts success of phase 3 trial of Sunosi in ADHD, adding to 'string of recent wins' | 3 | FiercePharma | ||
| 17:06 | What's Going On With Alumis Shares Tuesday? | 1 | Benzinga.com | ||
| 16:46 | Axsome-Aktien fallen nach Ergebnissen der ADHS-Studie | 7 | Investing.com Deutsch | ||
| 16:42 | Axsome shares fall after ADHD trial results | 1 | Investing.com | ||
| 16:06 | CorMedix shares tumble after order delay | 4 | Investing.com | ||
| 16:06 | Axsome Therapeutics Lower Dose Of Attention Deficient Disorder Candidate Hits Primary Goal | 2 | Benzinga.com | ||
| 16:00 | CorMedix targets $50M-$60M revenue for H1 2025 with DefenCath growth | 2 | Seeking Alpha | ||
| 15:58 | CorMedix-Aktien fallen nach Bestellverzögerung | 3 | Investing.com Deutsch | ||
| 15:46 | Alumis and Kaken sign agreement in Japan to develop ESK-001 | 1 | Pharmaceutical Technology | ||
| 15:42 | $1000 Invested In Insmed 10 Years Ago Would Be Worth This Much Today | 1 | Benzinga.com | ||
| 15:42 | AstraZeneca to Invest $2.5B in New Global R&D Center in Beijing | 3 | Contract Pharma | ||
| 15:12 | Scholar Rock gets FDA priority review for its spinal muscular atrophy treatment | 2 | Seeking Alpha | ||
| 14:59 | CorMedix Dives on Results | 3 | Baystreet.ca | ||
| 14:45 | HC Wainwright Reiterates Buy Rating for Aura Biosciences (NASDAQ:AURA) | 1 | MarketBeat |
Seite:
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
